Nurix Therapeutics falls 2% following Q3 earnings as operating expenses up
Nurix Therapeutics (NRIX) reported Q3 2026 revenue of $673.1M, up from $7.9M YoY, with adjusted EPS of $4.73 vs. a loss of -$1.03. Shares fell 2% after hours, despite an 8% intraday gain. Revenue growth was driven by license revenue from Roche and a milestone payment from Sanofi. Operating expenses increased due to one-time costs related to the Roche transaction. The company has $1.1B in cash, providing runway into 2H 2029.
How this was made
The 30-second read
Why it matters
The earnings release provides fresh data on revenue growth and cash position, influencing short‑term price action.
Market read
First‑report earnings with significant revenue jump and modest share decline; actionable for traders.
What to watch
Cash runway to 2029 and reduced R&D spend may support longer-term upside.
Background
Nurix Therapeutics reported a dramatic increase in license revenue from Roche and a milestone from Sanofi, while G&A expenses rose due to one‑time transaction costs.
Ticker impact
Q3 2026 earnings released with revenue $673.1M (up from $7.9M) and shares down 2% after hours.
likely modest pressure as investors digest higher expenses and mixed guidance
The stock fell 2% after the release despite strong revenue, indicating market concern over cost structure.
Market effects
Biotech licensing revenue surge may boost peers with similar collaboration models.
US biotech sector sees modest uplift from strong licensing deals.
Limited to biotech investors; no broad market effect.
Counterpoint
The revenue jump could signal a turning point; the 2% dip may be an overreaction.
Key entities
- companyNurix Therapeutics
Biotech firm reporting Q3 2026 earnings.
- partnerRoche
Collaboration partner providing license revenue.
- partnerSanofi
Provided a $10M development milestone.
